Activities of Daptomycin and Vancomycin Alone and in Combination with Rifampin and Gentamicin against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus Isolates in an Experimental Model of Endocarditis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The findings of clinical and in vitro research support the theory that infective endocarditis (IE)-causing bacteria form biofilms and that biofilms negatively affect treatment outcomes. The purpose of the present study was to quantify the biofilm formation of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) isolates obtained from patients with IE and to evaluate the in vitro activities of daptomycin and vancomycin alone and in combination with rifampin (rifampicin) or gentamicin while monitoring the isolates for the development of resistance. A high-inoculum, stationary-phase infection model of IE was used to simulate the pharmacokinetics in humans of daptomycin at 6 mg/kg of body weight/day, vancomycin at 1.25 g every 12 h (q12h) alone and in combination with rifampin at 300 mg every 8 h, and gentamicin at 1.3 mg/kg q12h. Two randomly selected clinical MRSA isolates were obtained from patients with IE; both MRSA isolates quantitatively produced biofilms. The time to bactericidal activity in the presence of daptomycin was isolate dependent but was achieved by 24 h for both MRSA isolates. Vancomycin did not achieve bactericidal activity throughout the experiment. At 24, 48, and 72 h, daptomycin-containing regimens had significantly more activity (greater declines in the mean number of CFU/g) than any of the vancomycin-containing regimens ( P = 0.03). Rifampin and gentamicin antagonized or delayed the bactericidal activity of daptomycin (against MRSA B346846 for rifampin and against both isolates for gentamicin) in the first 24 h. Increases in the daptomycin and vancomycin MICs were not observed. We conclude that in an IE model of biofilm-forming MRSA, daptomycin monotherapy has better in vitro activity than daptomycin in combination with rifampin or gentamicin or any vancomycin-containing regimen studied within the first 24 h. Further investigations are needed to understand the initial delay in bactericidal activity observed when gentamicin or rifampin is combined with daptomycin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, fluoroquinolones and aminoglycoside antibiotics are less affected by the size of the inoculum because of their different mechanisms of bactericidal activity. 81,82”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 2×
“The exact cause of most treatment failures is unknown; however, it is likely related to the ability of the bacteria to form biofilms (14, 19).”
BackgroundSTEPANOVIĆ, S., VUKOVIĆ, D., HOLA, V., BONAVENTURA, G. D., DJUKIĆ, S., ĆIRKOVIĆ, I., & RUZICKA, F. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_630.x · Cited by 2,494
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Götz, F. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02827.x · Cited by 1,178
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Jarraud, S., Mougel, C., Thioulouse, J., Lina, G., Meugnier, H., Forey, F., Nesme, X., Etienne, J., & Vandenesch, F. (2002) · Infection and Immunity · doi:10.1128/iai.70.2.631-641.2002 · Cited by 1,151
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Quorum Sensing in Staphylococcus aureus Biofilms
Yarwood, J. M., Bartels, D. J., Volper, E. M., & Greenberg, E. P. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.6.1838-1850.2004 · Cited by 597
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Staphylococcus aureus resistant to vancomycin--United States, 2002.
(2002) · PubMed · Cited by 569
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Resistance of bacterial biofilms to antibiotics a growth-rate related effect?
BROWN, M. R. W., ALLISON, D. G., & GILBERT, P. (1988) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/22.6.777 · Cited by 545
Quorum sensing in Staphylococcus infections
Yarwood, J. M., & Schlievert, P. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320442 · Cited by 400
Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling
Kizana, E., Ginn, S. L., Allen, D. G., Ross, D. L., & Alexander, I. E. (2005) · Circulation · doi:10.1161/01.cir.0000153812.64956.ef · Cited by 382
Clinical Pharmacokinetics of Vancomycin
Matzke, G. R., Zhanel, G. G., & Guay, D. R. P. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611040-00001 · Cited by 360 · cited 2×
“These results are consistent with those presented in other reports (24) and may be explained by the relatively high and moderate levels of protein binding exhibited by daptomycin (93%) and vancomycin (55%), respectively (15, 27).”
BackgroundResultDvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Raad, I., Hanna, H., Jiang, Y., Dvorak, T., Reitzel, R., Chaiban, G., Sherertz, R., & Hachem, R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00350-06 · Cited by 350
Biofilm resistance to antimicrobial agents
Xu, K. D., McFeters, G. A., & Stewart, P. S. (2000) · Microbiology · doi:10.1099/00221287-146-3-547 · Cited by 325
Jefferson, K. K., Goldmann, D. A., & Pier, G. B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2467-2473.2005 · Cited by 319 · cited 1×
“Although vancomycin has commonly been used since the 1980s for the treatment of MRSA infections, including endocarditis, several published studies indicate that it has limited efficacy because of bacterial resistance, bacterial tolerance, and poor tissue penetration (8, 22, 36).”
BackgroundLaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Self-citationPerlroth, J., Kuo, M., Tan, J., Bayer, A. S., & Miller, L. G. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.805 · Cited by 212
Ribera, E., Gomez-Jimenez, J., Cortes, E., del Valle, O., Planes, A., Gonzalez-Alujas, M. T., Almirante, B., Ocana, I., & Pahissa, A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-12-199612150-00005 · Cited by 187
Pharmacokinetics of Rifampin Under Fasting Conditions, With Food, and With Antacids
Peloquin, C. A., Namdar, R., Singleton, M. D., & Nix, D. E. (1999) · Chest · doi:10.1378/chest.115.1.12 · Cited by 178
Blaser, J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.125 · Cited by 156
Smith, K., Perez, A., Ramage, G., Gemmell, C. G., & Lang, S. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.08.029 · Cited by 137
Fortún, J., Navas, E., Martínez‐Beltrán, J., Pérez‐Molina, J., Martín‐Dávila, P., Guerrero, A., & Moreno, S. (2001) · Clinical Infectious Diseases · doi:10.1086/320869 · Cited by 126 · cited 2×
“This has been observed in clinical studies (16) and in vitro studies (34) with vancomycin, but to our knowledge, this has not yet been observed with daptomycin.”
ResultDandekar, P. K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg337 · Cited by 119
LaPlante, K. L., & Mermel, L. A. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm141 · Cited by 100
Self-citationENDOCARDITIS DUE TOCOAGULASE-NEGATIVE STAPHYLOCOCCI
Whitener, C., Caputo, G. M., Weitekamp, M. R., & Karchmer, A. W. (1993) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30507-9 · Cited by 98
Rose, W. E., Leonard, S. N., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00102-08 · Cited by 90
McGrath, B. J., Kang, S., Kaatz, G. W., & Rybak, M. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2034 · Cited by 62
Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp.
Roveta, S., Marchese, A. E., & Schito, G. C. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.11.012 · Cited by 52
Murillo, Ó., Pachón, M. E., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., Gudiol, F., & Ariza, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00458-08 · Cited by 49
Cafini, F., Aguilar, L., González, N., Giménez, M.-J., Torrico, M., Alou, L., Sevillano, D., Vallejo, P., & Prieto, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm078 · Cited by 45
Hershberger, E., Coyle, E. A., Kaatz, G. W., Zervos, M. J., & Rybak, M. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1921-1924.2000 · Cited by 38
Wald, E. R., Standiford, H. C., Tatem, B. A., Calia, F. M., & Hornick, R. B. (1975) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.7.3.336 · Cited by 34
Tsuji, B. T., Leonard, S. N., Rhomberg, P. R., Jones, R. N., & Rybak, M. J. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.11.011 · Cited by 33
Bayer, A. S., & Norman, D. C. (1990) · CHEST Journal · doi:10.1378/chest.98.1.200 · Cited by 31
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY: 2008 INSTRUCTIONS TO AUTHORS
(2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01407-07 · Cited by 19
Research works printed but not linked: 2
- Performance standards for antimicrobial susceptibility testing; 16th informational supplement. 2006 vol. 26
- 10.1172/jci20442 · doi:10.1172/jci20442 · Paper page
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
New approaches for treating staphylococcal biofilm infections
Kiedrowski, M. R., & Horswill, A. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06281.x · Cited by 288
Anti-biofilm Activity as a Health Issue
Miquel, S., Lagrafeuille, R., Souweine, B., & Forestier, C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00592 · Cited by 225
JCS 2017 Guideline on Prevention and Treatment of Infective Endocarditis
Nakatani, S., Ohara, T., Ashihara, K., Izumi, C., Iwanaga, S., Eishi, K., Okita, Y., Daimon, M., Kimura, T., Toyoda, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0549 · Cited by 179
Metadata
- Authors
- LaPlante, K. L., & Woodmansee, S.
- Affiliations
- University of Rhode Island (US)
- Providence VA Medical Center (US)
- Corresponding author
- LaPlante, Kerry L.
- ORCID
- LaPlante, Kerry L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-09
- Volume
- 53
- Issue
- 9
- Pages
- 3880-3886
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2737833
- OpenAlex
- W2133736791
- Semantic Scholar
- 493a2fe713337d2af29722aa84a1ae225e629305
- Cited by
- 110
- References
- 44
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 6 · 2016: 11 · 2015: 15 · 2014: 11 · 2013: 8 · 2012: 5
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Journal of Media Literacy Education (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- University of Wisconsin-Madison
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- daptomycin, vancomycin, rifampicin, gentamicin, methicillin-resistant Staphylococcus aureus, infective endocarditis, biofilm formation, combination antibiotic therapy, bactericidal activity, antibiotic resistance development, in vitro antimicrobial susceptibility, monotherapy versus combination therapy
- MeSH terms
- Anti-Bacterial Agents, Endocarditis, Gentamicins, Humans, Microbial Sensitivity Tests, Rifampin, Vancomycin, Daptomycin, Biofilms, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.